BioLine RX Ltd Cash Flow Reinvestment Rate

Latest as of December 2023: 4.09x

BioLine RX Ltd cash flow reinvestment rate. BioLine RX Ltd (BLRX) has a Cash Flow Reinvestment Rate of 4.09x as of December 2023, reinvesting ILA20.41 Million (capex ILA18.00K plus investments ILA-20.39 Million) from operating cash flow of ILA4.99 Million. Explore BioLine RX Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

4.09x
(Capex + Investments) / Operating CF

Total Reinvested

ILA20.41 Million
Capex + Investments

Operating Cash Flow

ILA4.99 Million
ILA

Capital Expenditures

ILA18.00K
ILA

Cash Flow Reinvestment Rate of BioLine RX Ltd (2010–2010)

Cash flow reinvestment rate of BioLine RX Ltd from 2010 to 2010. Historical reinvestment intensity for BioLine RX Ltd across 1 annual periods. Explore BLRX capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

BioLine RX Ltd Cash Flow Reinvestment Rate by Year (2010–2010)

BioLine RX Ltd cash flow reinvestment rate by year from 2010 to 2010. Year-by-year capital reinvestment analysis for BioLine RX Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of BioLine RX Ltd.

Year Reinvestment Rate Total Reinvested (ILA) Operating CF Capex YoY Change
2010 0.06x ILA660.94K ILA11.46 Million ILA660.94K —
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow